XBITNasdaqPharmaceutical PreparationsFiscal year ends December 31
XBiotech Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.00−0.12 (-5.66%)
Close on Oct 19, 2026
- Market cap
- $60.98M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.49 (−19.68%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $60.98M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.47
- Dividend yield
- –
- Free cash flow yield
- -66.98%
Fundamentals
- Net income
- -$45.13M
- EPS, diluted
- -$1.48
- Free cash flow
- -$40.84M
- Book value per share
- $4.21
- Diluted shares
- 30M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$48.22M
Net income
-$45.13M
EPS, diluted
-$1.48
Free cash flow
-$40.84M
Reported periodTrailing twelve months